Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148638 | 0.81 | ALDH1A1 (0.63) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL10061921 | 0.79 | SMN1; SMN2 (0.67) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL12396814 | 0.78 | ESR1 (0.63) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3577679 | 0.77 | MAPT (0.48) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL9868598 | 0.77 | NPC1 (0.53) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL2588586 | 0.77 | GPR119 (0.59) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL29819579 | 0.76 | TLR9 (0.60) | GPR119MEN1RAB9AKMT2A | |
| SCHEMBL28831170 | 0.76 | TLR9 (0.60) | GPR119MEN1RAB9AKMT2A | |
| SCHEMBL3666752 | 0.76 | F2 (0.49) | HSD17B10KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3671723 | 0.76 | GAA (0.50) | KDM4EALDH1A1MAPTMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590980-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | HSD17B10 2545/4885KDM4E 980/4885ALDH1A1 3938/4885 |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | HSD17B10 2495/4885KDM4E 1261/4885ALDH1A1 3913/4885 |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | HSD17B10 2545/4885KDM4E 980/4885ALDH1A1 3938/4885 |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | CYP11B2, CYP11B1, CYP4B1 | HSD17B10 146/4885KDM4E 3077/4885ALDH1A1 890/4885 |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | HSD17B10 2678/4885KDM4E 2318/4885ALDH1A1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.